Disease relevance of Maxolon

• Patients given metoclopramide had significantly fewer episodes of emesis than patients given placebo (medians, 1.0 vs. 10.5; P = 0.001) or prochlorperazine (medians, 1.5 vs. 12.0; P = 0.005) [1].
• More on metoclopramide and tardive dyskinesia [2].
• Since metoclopramide increases lower-esophageal-sphincter pressure in patients with gastroesophageal reflux, we compared the effects of metoclopramide, 10 mg four times daily, with those of placebo on symptoms in 31 patients with chronic heartburn [3].
• Hypertension after metoclopramide [4].
• A total of 165 women with breast cancer from 14 Canadian centers who were about to receive this chemotherapy for the first time were randomly assigned to receive either ondansetron (n = 85) or dexamethasone plus metoclopramide (n = 80), a widely used, standard antiemetic regimen [5].

Psychiatry related information on Maxolon

• Akathisia and metoclopramide [6].
• Metoclopramide and bethanecol significantly increased gastric motor activity in these patients, often triggering an intense burst of motor activity in the stomach, similar to phase III [7].
• When bethanechol or metoclopramide was given 10 min before the complex liquid meal, there was a paucity of contractile activity, gastric emptying was slow, and symptoms of lethargy, diaphoresis, and retching were present [8].
• Can metoclopramide reveal Huntington's disease [9]?
• Administration of metoclopramide resulted in a slight reduction of REM sleep to 16-17%, whereas wakefulness after sleep onset increased [10].

High impact information on Maxolon

• We conclude that metoclopramide in high intravenous doses has greater antiemetic activity than placebo or prochlorperazine in patients receiving cisplatin chemotherapy [1].
• A controlled trial of metoclopramide in symptomatic gastroesophageal reflux [3].
• Urinary incontinence associated with metoclopramide [11].
• Combination of glucagon and low-dose metoclopramide in management of cisplatin-induced nausea and vomiting [12].
• We therefore studied the effects of oral metoclopramide given at doses of 20, 50, or 100 mg four times a day for 25 doses (7 days) beginning after cisplatin to determine the maximum tolerated dose (MTD) for prophylactic oral antiemetic regimens [13].

Chemical compound and disease context of Maxolon

• Acute akathisia after oral droperidol and metoclopramide preoperative medication [14].
• Continuous versus intermittent infusion of high-dose metoclopramide in prevention of cisplatin-induced emesis [15].
• Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum. A comparison with metoclopramide and placebo [16].
• Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol [7].
• Amiodarone, metoclopramide, and renal failure [17].

Biological context of Maxolon

• Eleven additional reflux patients with delayed gastric emptying received oral metoclopramide, 10 mg, in an open-labeled fashion [18].
• Pharmacokinetics of metoclopramide [19].
• Metoclopramide therapy may be useful for improving poor lactation [20].
• We also investigated the effect of metoclopramide on plasma motilin concentration and gastrointestinal motility in these patients [21].
• The stress-induced inhibition of migrating motor complexes was reversed by oral metoclopramide; however, the drug did not reverse the cardiovascular or subjective response to stress [22].

Anatomical context of Maxolon

• These studies suggest that in the opossum, metoclopramide acts through a direct action on the smooth muscle [23].
• In a placebo-controlled, cross-over study, thirty-seven puerperal women with inadequate production of breast-milk were treated with 5, 10, or 15 mg of metoclopramide three times a day for 2 weeks [20].
• Oral metoclopramide, however, failed to increase the amplitude of esophageal contractions and acid clearing of the distal esophagus [24].
• Intravenous metoclopramide (M) was compared to placebo (P) by a double blind crossover design to determine whether M was superior to P in difficult cases of intubation of the small intestine, using a multipurpose biopsy tube and capsule [25].
• Metoclopramide may improve symptoms of diabetic gastric stasis through two mechanisms: its peripheral effect on gastric smooth muscle, which increases gastric emptying; and its central effects on the chemoreceptor vomiting zone, which decrease nausea [26].

Associations of Maxolon with other chemical compounds

• Thus, 25 of 38 patients (66%) receiving 59 of 83 courses (71%) of cisplatin-containing chemotherapy attained either total or major antiemetic protection with metoclopramide [27].
• In addition, agonist responses were studied in the presence of the selective DA2 receptor antagonist domperidone, a mixed DA1/DA2 receptor antagonist metoclopramide, and the selective DA1 receptor antagonists bulbocapnine and SK&F 83566 [28].
• There was considerable intersubject variability in gastric emptying responses to cisapride and metoclopramide [16].
• Thirteen reflux patients with delayed gastric emptying received metoclopramide, 10 mg intramuscularly, and subcutaneous bethanechol, 0.07 mg/kg, in a randomized single-blind fashion [18].
• After parenteral metoclopramide, gastric emptying was significantly (p less than 0.05) faster compared with both the initial basal day and the bethanechol treatment day [18].

Gene context of Maxolon

• To determine whether dopaminergic inhibition contributed to the reduced TSH and PRL responsiveness in the acute withdrawal state, six additional chronic alcoholic men were tested with oral metoclopramide [29].
• Insulin hypoglycemia stimulated and metoclopramide inhibited both GH and GHRH acutely [30].
• In analogy to the TSH behavior, plasma PRL secretion in response to metoclopramide and TRH administration was significantly (p less than 0.05) inhibited in the subclinical hypothyroid patients after l-thyroxine replacement therapy [31].
• This study aimed to evaluate PRL and GH secretion after metoclopramide and thyrotrophin-releasing hormone (TRH) infusion in infertile patients with minimal/mild endometriosis [32].
• Metoclopramide is a potent inhibitor of CYP2D6 at therapeutically relevant concentrations (K(i) = 4.7 +/- 1.3 microM), with negligible effect on other isoforms tested [33].

Analytical, diagnostic and therapeutic context of Maxolon

• In both treatment periods, metoclopramide-treated patients had significantly more symptomatic improvement than the control group (P less than 0.05) [3].
• A double blind crossover study of metoclopramide versus placebo for facilitating passage of multipurpose biopsy tube [25].
• Oral administration of metoclopramide resulted in a significant improvement in gastric emptying of the solid meal and a nonsignificant trend toward more rapid liquid emptying, but no change in esophageal emptying [34].
• We evaluated whether chronic nausea and vomiting in diabetic patients correlate with abnormal gastric emptying of liquid or solid, or both liquid and solid, radiolabeled meals and recorded the acute effects of metoclopramide. last, we compared several methods of analyzing gastric emptying data obtained using the gamma-camera [35].
• The effect of metoclopramide, a stimulant of gastric motility, on gastric emptying was tested in 6 patients with chronic gastric retention after vagotomy and gastric resection, unexplained by mechanical obstruction or stomal ulceration [36].

References